Curcumol inhibits hepatocellular carcinoma proliferation through miRNA-124/STAT3 pathway: Network pharmacology and experimental validation

IF 3.6 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Gui-yu Li , Ji-yong Lin
{"title":"Curcumol inhibits hepatocellular carcinoma proliferation through miRNA-124/STAT3 pathway: Network pharmacology and experimental validation","authors":"Gui-yu Li ,&nbsp;Ji-yong Lin","doi":"10.1016/j.crbiot.2024.100270","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Hepatocellular carcinoma <strong>(</strong>HCC) is the most common type of liver cancer and is one of the most common global cancers. <em>Curcuma zedoaria (Christm.) Roscoe</em> is a traditional Chinese herb that has been used for thousands of years in China to treat various types of cancer. Curcumol is one of its primary bioactive sesquiterpenes and has been reported to possess antitumor properties; however, the underlying mechanisms in hepatocellular carcinoma (HCC) are largely unknown. The aim of this study was to reveal the mechanism of curcumol treating HCC based on the network pharmacology and experimental verification.</div></div><div><h3>Materials and Methods</h3><div>Targets of HCC and curcumol were identified. The drugs and disease targets were intersected by <em>Venn Diagram.</em> The KEGG pathway enrichment analysis of curcumol treating HCC was analyzed through the R 3.6.1 software. The effects of curcumol on the inhibition of HCC cell line HepG2 growth and its pro-apoptotic activity were evaluated by cell counting kit-8 and flow cytometry. The expression of microRNA-124 (miRNA-124) mRNA was detected by quantitative real-time PCR. HepG2 cells were transfected with a miRNA mimic and inhibitor. The expression of STAT3 and its phosphorylation were induced by IL-6 and detected by western blotting.</div></div><div><h3>Results</h3><div>MicroRNAs in cancer is a significant enrichment signaling pathway for curcumol treating HCC, according to the KEGG pathway analysis. Curcumol effectively inhibited HepG2 cell growth at 50–150 μg/ml, while it had low toxicity to normal LO2 cells. Using flow cytometry, curcumol strongly promoted apoptosis in HepG2 cells and was more potent than the miRNA-124 mimic, whereas the miRNA-124 inhibitor reduced the pro-apoptotic effect of curcumol. Western blotting revealed that curcumol significantly downregulated the overexpression of STAT3 and its phosphorylation in interleukin-6 induced HepG2 cells, whereas an increased level of STAT3 was observed in the miRNA-124 inhibitor transfected cells after curcumol treatment compared to untransfected cells. The level of miRNA-124 was changed up to 5.87-fold by curcumol treatment.</div></div><div><h3>Conclusions</h3><div>The mechanism underlying the effect of curcumol on inhibition and pro-apoptosis of HepG2 cell growth is possibly related to the miRNA-124/STAT3 pathway.</div></div>","PeriodicalId":52676,"journal":{"name":"Current Research in Biotechnology","volume":"9 ","pages":"Article 100270"},"PeriodicalIF":3.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590262824000960","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is one of the most common global cancers. Curcuma zedoaria (Christm.) Roscoe is a traditional Chinese herb that has been used for thousands of years in China to treat various types of cancer. Curcumol is one of its primary bioactive sesquiterpenes and has been reported to possess antitumor properties; however, the underlying mechanisms in hepatocellular carcinoma (HCC) are largely unknown. The aim of this study was to reveal the mechanism of curcumol treating HCC based on the network pharmacology and experimental verification.

Materials and Methods

Targets of HCC and curcumol were identified. The drugs and disease targets were intersected by Venn Diagram. The KEGG pathway enrichment analysis of curcumol treating HCC was analyzed through the R 3.6.1 software. The effects of curcumol on the inhibition of HCC cell line HepG2 growth and its pro-apoptotic activity were evaluated by cell counting kit-8 and flow cytometry. The expression of microRNA-124 (miRNA-124) mRNA was detected by quantitative real-time PCR. HepG2 cells were transfected with a miRNA mimic and inhibitor. The expression of STAT3 and its phosphorylation were induced by IL-6 and detected by western blotting.

Results

MicroRNAs in cancer is a significant enrichment signaling pathway for curcumol treating HCC, according to the KEGG pathway analysis. Curcumol effectively inhibited HepG2 cell growth at 50–150 μg/ml, while it had low toxicity to normal LO2 cells. Using flow cytometry, curcumol strongly promoted apoptosis in HepG2 cells and was more potent than the miRNA-124 mimic, whereas the miRNA-124 inhibitor reduced the pro-apoptotic effect of curcumol. Western blotting revealed that curcumol significantly downregulated the overexpression of STAT3 and its phosphorylation in interleukin-6 induced HepG2 cells, whereas an increased level of STAT3 was observed in the miRNA-124 inhibitor transfected cells after curcumol treatment compared to untransfected cells. The level of miRNA-124 was changed up to 5.87-fold by curcumol treatment.

Conclusions

The mechanism underlying the effect of curcumol on inhibition and pro-apoptosis of HepG2 cell growth is possibly related to the miRNA-124/STAT3 pathway.

Abstract Image

求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Research in Biotechnology
Current Research in Biotechnology Biochemistry, Genetics and Molecular Biology-Biotechnology
CiteScore
6.70
自引率
3.60%
发文量
50
审稿时长
38 days
期刊介绍: Current Research in Biotechnology (CRBIOT) is a new primary research, gold open access journal from Elsevier. CRBIOT publishes original papers, reviews, and short communications (including viewpoints and perspectives) resulting from research in biotechnology and biotech-associated disciplines. Current Research in Biotechnology is a peer-reviewed gold open access (OA) journal and upon acceptance all articles are permanently and freely available. It is a companion to the highly regarded review journal Current Opinion in Biotechnology (2018 CiteScore 8.450) and is part of the Current Opinion and Research (CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists' workflow.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信